Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
LOXL3
REST API REST API
Homo sapiens
LOXL3 is differentially expressed in 139 experiments: 55 organism parts: bone marrow, cerebellum, ... (53 more);, 70 disease states: normal, glioblastoma, ... (68 more);, 46 cell types 223 cell lines 11 compound treatments and 39 other conditions.
Orthologs Loxl3 (Rattus norvegicus)   ENSCING00000006336 (Ciona intestinalis)   LOXL3 (Bos taurus)   LOXL3 (Gallus gallus)   lox2 (Drosophila melanogaster)   Loxl3 (Mus musculus)   loxl3b (Danio rerio)   LOXL3 (Canis familiaris)   loxl3 (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term oxidoreductase activity, scavenger receptor activity, extracellular space, membrane, metal ion binding, extracellular region, oxidoreductase activity, acting on the CH-NH2 group of donors, oxygen as acceptor, biological_process, protein-lysine 6-oxidase activity, copper ion binding, oxidation-reduction process
InterPro Term Lysyl_oxidase, Srcr_rcpt, Srcr_rcpt-rel
UniProt Accession B9A025, Q53TY1, Q6IPL7, C9J5M1, Q8N505, P58215, Q2EHP2, B8ZZT6, E7END4
Search EB-eye ENSG00000115318
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-8167, E-MTAB-37, E-GEOD-6573, E-GEOD-18105, E-MTAB-69, ... (12 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-19639, E-GEOD-24147, E-GEOD-19480, ... (20 experiments)

Factor Value U/D Experiments
A549
2
E-GEOD-6013, E-GEOD-3202
MKN45
1
E-GEOD-15460
NCIH2107
1
E-MTAB-37
U-937
1
E-GEOD-24147
CFT-2
1
E-MEXP-980
GCT
1
E-MTAB-37
217 more value(s).


Cell type

studied in E-TABM-40, E-GEOD-21668, E-GEOD-20677, E-GEOD-13909, E-GEOD-13987, ... (25 experiments)

Factor Value U/D Experiments
stromal cell
3
E-MEXP-2034, E-GEOD-1460, E-GEOD-3998
human foreskin fibroblast
2
E-GEOD-18147, E-GEOD-18265
memory B cell
1
E-TABM-702
mature monocyte derived dendritic cell
1
E-GEOD-4984
CD326negCD56+ cell
1
E-GEOD-21668
pro B cell
1
E-MEXP-1403
40 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-MEXP-2069, E-GEOD-22148, E-MTAB-680, ... (30 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-GEOD-4290, E-MTAB-37, E-GEOD-4412
gastric carcinoma
2
E-MTAB-37, E-GEOD-15460
prostate carcinoma
2
E-GEOD-7307, E-MEXP-2034
subependymal giant cell astrocytoma
1
E-MEXP-2351
FKRP mutation
1
E-GEOD-3307
gulf war illness
1
E-MEXP-2069
64 more value(s).


Compound treatment

studied in E-MEXP-1601, E-MEXP-1230, E-GEOD-5099, E-MEXP-2241, E-MEXP-1958, ... (7 experiments)

Factor Value U/D Experiments
TTA
1
E-MEXP-2590
ethanol
1
E-MEXP-2241
lipopolysaccharide
1
E-MEXP-1958
none
2
2
E-MEXP-1958, E-MEXP-1230, E-MEXP-1601, E-GEOD-7307
SDF + Cxcr4
1
E-GEOD-7307
NaOH
1
E-MEXP-2590
5 more value(s).


BioSourceProvider

studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Factor Value U/D Experiments
Coriell: GM12814
1
E-GEOD-19519
Coriell: GM11992
1
E-GEOD-19519
Coriell: GM14481
1
E-GEOD-19519
Coriell Cell Repositories http://ccr.coriell.org/Sections/Search/Search.aspx?PgId=165&q=NA19098
1
E-GEOD-19480
Coriell: GM14406
1
E-GEOD-19519
Coriell Cell Repositories http://ccr.coriell.org/Sections/Search/Search.aspx?PgId=165&q=NA18508
1
1
E-GEOD-19480
69 more value(s).


Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-16363, E-GEOD-19665

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743

Estrogen receptor status
studied in E-GEOD-6532

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-GEOD-7578, E-GEOD-20847, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-GEOD-17476, E-MEXP-421, E-GEOD-18736, E-GEOD-17347, E-MEXP-1403 ... (5 experiments)

Growth condition
studied in E-MEXP-2657, E-GEOD-20540, E-GEOD-9764, E-GEOD-10315

Histology
studied in E-TABM-234

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-TABM-666, E-MEXP-1648, ... (14 experiments)

Infection
studied in E-GEOD-12108

Injury
studied in E-GEOD-19743

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Original diagnosis
studied in E-GEOD-21521

Phenotype
studied in E-GEOD-1657, E-GEOD-17636, E-MEXP-1403

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-19246

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-2115

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-12198

Tumor grading
studied in E-GEOD-4290

Processing time: 0.35 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM